"Anyone with lungs can get lung cancer, yet lung cancer continues to receive less research funding compared to other cancers.

Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

“EGFR” stands for “epidermal growth factor receptor.” The EGFR gene controls the production of EGFR proteins, which are found in both healthy and abnormal cells. They help cells grow and divid ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported 2024 results in a February press release highlighting several achievements and company goals. The Phase Ib clinical trial for ...

Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Taiwanese researchers have linked higher survival rates and decreased tumor spread in patients with adenocarcinoma of the ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

In episode four of Chat!DNA, an interview series by BGI Genomics, we feature Lin Cong, whose research on colorectal cancer, ...